Adial Pharmaceuticals (NASDAQ: ADIL) grants 10-year hire option at $5.76
Rhea-AI Filing Summary
Adial Pharmaceuticals, Inc. (ADIL) reported granting a stock option as a material inducement for a new employee to join the company. On August 19, 2026, the company granted an option to purchase 307,814 shares of common stock at an exercise price of $5.76 per share, the closing price on the grant date. The option has a ten-year term and will vest over four years, with 25% vesting on the first anniversary of the grant date and the remainder vesting in equal monthly installments thereafter, subject to continued service. The grant was made outside the company’s equity incentive plans under the employment inducement exception in Nasdaq Listing Rule 5635(c)(4) and relies on an exemption from registration under Section 4(a)(2) of the Securities Act and Regulation D. The option and underlying shares may not be sold in the United States without registration or an applicable exemption.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 3.02 — Unregistered Sales of Equity Securities
1 item
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Key Figures
Inducement option shares: 307,814 shares
Exercise price: $5.76 per share
Option term: 10 years
+2 more
5 metrics
Inducement option shares
307,814 shares
Option to purchase common stock granted August 19, 2026
Exercise price
$5.76 per share
Closing price of ADIL common stock on August 19, 2026
Option term
10 years
Ten-year term for the inducement option
Initial vesting portion
25%
Vests on the first anniversary of the grant date
Grant date
August 19, 2026
Effective date of the inducement option grant
Key Terms
employment inducement exception, Nasdaq Listing Rule 5635(c)(4), Section 4(a)(2) of the Securities Act, Regulation D
4 terms
employment inducement exception regulatory
"in reliance on the employment inducement exception to shareholder approval"
A stock-exchange listing rule that lets a company give equity awards to newly hired executives or employees as a recruitment incentive without prior shareholder approval. Think of it like a hiring bonus paid in stock options or restricted shares that sits outside the company’s existing, shareholder-approved equity plan; exchanges cap the size and require public disclosure. It matters to investors because these grants can dilute existing holdings and reveal how a company is using stock to attract talent.
Nasdaq Listing Rule 5635(c)(4) regulatory
"exception to shareholder approval provided under Nasdaq Listing Rule 5635(c)(4)"
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
Section 4(a)(2) of the Securities Act regulatory
"in reliance on an exemption from registration under Section 4(a)(2) of the Securities Act"
A legal exemption that allows a company to sell securities directly to a limited group of buyers without registering the offering with the Securities and Exchange Commission. Think of it like a private sale among known parties rather than a public auction: it can speed fundraising and reduce disclosure requirements, but it also means less public information, lower liquidity and resale restrictions—factors investors should consider when weighing risk and exit options.
Regulation D regulatory
"and Regulation D promulgated thereunder"
Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.
FAQ
What equity award did ADIL grant on August 19, 2026?
Adial Pharmaceuticals (ADIL) granted a stock option to purchase 307,814 shares of common stock to a new employee as a material inducement to employment, with a ten-year term and vesting over four years, subject to continued service.
What is the exercise price of the new ADIL stock option grant?
The exercise price of the Adial Pharmaceuticals (ADIL) inducement stock option is $5.76 per share, which equals the closing price of the company’s common stock on August 19, 2026, the effective date of grant.
How does the ADIL inducement option vest over time?
The Adial (ADIL) inducement option vests over four years: 25% vests on the first anniversary of the grant date, and the remaining 75% vests in equal monthly installments thereafter, conditioned on the employee’s continued service through each vesting date.
Was the ADIL inducement grant made under an existing equity plan?
No. Adial (ADIL) states the stock option inducement grant was made outside its equity incentive plans, relying on the employment inducement exception to shareholder approval under Nasdaq Listing Rule 5635(c)(4).
Is the ADIL inducement option registered under the Securities Act?
No. Adial (ADIL) indicates the option and underlying shares have not been registered under the Securities Act and were issued in reliance on Section 4(a)(2) and Regulation D. They cannot be sold in the U.S. without registration or an applicable exemption.
AI-generated analysis. How Rhea-AI works. Not financial advice.
